While articles and discussions on minimally invasive glaucoma surgery (MIGS) seem to be everywhere (for better or worse), “trabeculectomy will survive,” said Kuldev Singh, MD, because of the aging population, the ease of postoperative titration, and the need for even lower pressures.
The glaucoma device market is expected to grow at three to four times the rate of the refractive and cataract surgery and the IOL markets over the next few years, Dr. Singh said.
Dr. Singh’s presentation was part of the 23rd Annual Glaucoma Symposium at the 2019 Glaucoma 360 meeting. Dr. Singh is professor of ophthalmology and director of the Glaucoma Service, Stanford University School of Medicine, Palo Alto, CA. “We currently have 17 distinct procedures for glaucoma inflow/outflow procedures,” Dr. Singh pointed out. “We have non-device MIGS procedures, and we have lasers that reduce aqueous production.”
All of these procedures are leading to a “Glaucoma Restoration” period, likening the current state of glaucoma to a “Glaucoma Renaissance.”
“Not all these procedures and devices will survive,” he said. “There will always be a role for trabeculectomy as a result.”